Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Skye Bioscience, Inc.

Skye Bioscience is a biopharmaceutical company developing next-generation molecules to treat obesity and metabolic diseases. Self-described efforts focus on advancing first-in-class drugs to provide enhanced health outcomes.

Skye Bioscience

Skye Bioscience Inc. | 2,145 followers on LinkedIn. Unlocking new therapeutic pathways for metabolic health | Skye Bioscience (Nasdaq: SKYE) is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors.  Skye&#39;s strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye plans to start a Phase 2 clinical trial in obesity in Q3 2024 for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, comparing monotherapy and combination arms of nimacimab and a GLP-1R agonist (Wegovy®).

Annalisa Jenkins

Vice President, Regulatory Affairs & Quality Assurance

Rhea Williams

President & CEO at Skye Bioscience, Inc.

Punit Dhillon

Chief Financial Officer

Kaitlyn Arsenault, CPA

Skye Bioscience Inc.

Skye hosted a satellite presentation on Nov. 5th during ObesityWeek 2024. Discover how Skye's drug, nimacimab, stands out by achieving effective peripheral CB1 inhibition without central exposure (and its risk of neuropsychiatric adverse events), leading to powerful benefits: dose-dependent weight loss, fat mass reduction with lean mass preservation, and improved glycemic control. Watch our full presentation here: https://lnkd.in/gxx2PbdP

Preliminary data from Skye's newly-developed diet-induced obesity (DIO) model in mice fulfilled its initial objective of showing that peripheral CB1 inhibition achieves significant weight loss without relying on central activity and its risk of neuropsychiatric adverse events. Skye’s peripherally-targeting antibody, nimacimab, a CB1 inverse agonist and antagonist, achieved dose-dependent weight loss of up to 16% compared to vehicle. Read the full article here: https://bit.ly/4fQ49B9

We are looking forward to participating in upcoming healthcare conferences. Available webcasts will be accessible on our website. Click here to read the full article: https://bit.ly/3YAsgwH

“It is clear that with increased restriction from the brain, nimacimab provides a potential safety advantage over a small molecule approach..." Skye CEO, Punit Dhillon said. Read the full article here: https://bit.ly/47EeaOX

We are looking forward to our formal presentation and investor meetings at #CantorHCC where Punit and Puneet will be representing Skye. View the webcast live on Sept 19 at 8:35am ET or the archive: https://lnkd.in/gRxa-jea

Skye looks forward to its fireside chat and meetings at Morgan Stanley on Friday, September 6th at 1:50 pm ET. Join the Webcast here, or watch the archived version: https://lnkd.in/gkFax6_C #MSHealthcare

Skye welcomes Puneet S. Arora, MD, MS, FACE, in the newly created role of Chief Medical Officer (CMO). Dr. Arora was previously at Lassen Therapeutics, Principia Biopharma, a Sanofi company, and Genentech. He is an endocrinologist with extensive experience in metabolic diseases, including obesity. Read the full article here: https://bit.ly/47es2PA

Skye will participate in the following upcoming healthcare investment conferences: - Morgan Stanley - Cantor Global Healthcare Conference - Bank of America World Medical Innovation Forum Available webcasts will be accessible on Skye’s website: https://bit.ly/3MiaecK

CBeyond(TM) will assess nimacimab’s ability to safely induce weight loss, and will also evaluate a combination of a GLP-1 receptor agonist plus nimacimab. Read the full article here: https://bit.ly/3T0hw8H

We're pleased to have broad sellside interest in nimacimab, our differentiated CB1 inhibitor focused on weight loss, and have a strong investment conference calendar through year-end.

	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue										124.25K -
gross profit										-124.25K -
selling and marketing expenses										-124.25K -
general and administrative expenses	2.50M -	3.74M 49.39%	3.53M 5.60%	3.55M 0.46%	4.36M 22.96%	4.39M 0.74%	4.34M 1.14%	4.92M 13.16%	6.09M 23.97%	7.85M 28.84%
selling general and administrative expenses	2.50M -	3.74M 49.39%	3.53M 5.60%	3.55M 0.46%	4.36M 22.96%	4.39M 0.74%	4.34M 1.14%	4.92M 13.16%	6.09M 23.97%	7.73M 26.80%
research and development expenses	227.50K -	576.09K 153.23%	939.04K 63.00%	311.30K 66.85%	329.97K 6.00%	2.24M 578.24%	1.94M 13.12%	2.93M 50.76%	6.01M 105.08%	5.82M 3.20%
other expenses		-1.00M -	-48.56K 95.16%	102.85K 311.78%						21.06M -
cost and expenses	2.73M -	4.32M 58.04%	4.47M 3.55%	3.86M 13.67%	4.69M 21.59%	6.63M 41.34%	6.29M 5.18%	7.85M 24.78%	12.11M 54.27%	13.67M 12.93%
operating expenses	2.73M -	4.32M 58.04%	4.47M 3.55%	3.86M 13.67%	4.69M 21.59%	6.63M 41.34%	6.29M 5.18%	7.85M 24.78%	12.11M 54.27%	13.55M 11.90%
interest expense		522.34K -	-1.29M 347.75%	667 100.05%	94.76K 14,107.35%	987.80K 942.39%	706.38K 28.49%	767.51K 8.65%	665.13K 13.34%	906.27K 36.25%
ebitda	-2.73M -	-4.79M 75.43%	-5.80M 21.08%	-3.75M 35.35%	-4.83M 28.81%	-6.64M 37.61%	-6.29M 5.37%	-7.82M 24.31%	-12.09M 54.73%	-13.55M 12.03%
operating income	-2.73M -	-4.32M 58.04%	-4.47M 3.55%	-3.86M 13.67%	-4.69M 21.59%	-6.63M 41.34%	-6.29M 5.18%	-7.85M 24.78%	-18.31M 133.34%	-13.67M 25.34%
depreciation and amortization	1.91K -	9.95K 421.65%	14.92K 49.86%	8.04K 46.10%	1.54K 80.79%	-11.42K 839.77%	1.90K 116.64%	32.49K 1,608.89%	6.22M 19,043.91%	124.25K 98.00%
total other income expenses net		-522.34K -	1.29M 347.75%	767.20K 40.72%	-14.27M 1,959.78%	7.69M 153.87%	-270.09K 103.51%	-672.37K 148.95%	-1.16M 72.99%	-23.97M 1,960.77%
income before tax	-2.73M -	-4.84M 77.16%	-3.18M 34.36%	-3.09M 2.64%	-19.19M 520.58%	1.05M 105.49%	-6.56M 722.65%	-8.52M 29.90%	-19.47M 128.58%	-37.64M 93.28%
income tax expense	2.50K -	1.72K 31.50%	1.60K 6.76%	1.60K 0%	1.64K 2.63%	1.60K 2.56%	1.60K 0%	2.10K 31.25%	6.74K 221%	3.60K 46.60%
net income	-2.73M -	-4.84M 77.06%	-3.18M 34.35%	-3.09M 2.64%	-19.19M 520.31%	1.05M 105.48%	-6.56M 723.74%	-8.52M 29.90%	-19.48M 128.60%	-37.64M 93.23%
weighted average shs out	10.29M -	16.94M 64.58%	18.95M 11.86%	27.91M 47.28%	121.15M 334.15%	135.15M 11.56%	230.75M 70.73%	406.60M 76.21%	555.27M 36.56%	7.01M 98.74%
weighted average shs out dil	10.29M -	16.94M 64.58%	18.95M 11.86%	27.91M 47.28%	121.15M 334.15%	169.56M 39.95%	231.42M 36.48%	406.60M 75.70%	555.27M 36.56%	7.01M 98.74%
eps	-0.27 -	-0.29 7.41%	-0.17 41.38%	-0.11 35.29%	-0.16 45.45%	0.01 104.88%	-0.03 464.10%	-0.02 26.06%	-0.04 67.14%	-5.37 15,199.15%
epsdiluted	-0.27 -	-0.29 7.41%	-0.17 41.38%	-0.11 35.29%	-0.16 45.45%	0.01 103.88%	-0.03 556.45%	-0.02 25.80%	-0.04 67.14%	-5.37 15,199.15%

SKYE

COM:SKYEBIOSCIENCE

Skye Bioscience

Last Close

4.17

22/11 21:00

Market Cap

81.91M

Beta: -

Volume Today

119.78K

Avg: -

Preview